PF-07284892 in Participants With Advanced Solid Tumors

Stopped The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue

Conditions

• Solid Tumor

Interventions

• DRUG: PF-07284892
• DRUG: lorlatinib
• DRUG: binimetinib
• BIOLOGICAL: cetuximab
• DRUG: encorafenib

Sponsor

Pfizer